Clinical application of antialdosterone-containing hormone therapy for postmenopausal women.
Increased awareness of the risk of cardiovascular disease (CVD) in postmenopausal women will aid clinicians in choosing the most appropriate hormone therapy (HT) for their patients. An antialdosterone-containing hormonal therapy offers postmenopausal women advantages beyond simply the relief of menopausal symptoms; drospirenone/estradiol therapy has a theoretical advantage for the modulation of postmenopausal cardiovascular target organ complications. Additionally, drospirenone/ estradiol therapy represents an attractive alternative to other forms of HT.
Minkin
Mary Jane
MJ
Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut, USA. maryjane.minkin@yale.edu
D000736:Androstenes / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D017698:Postmenopause / Q000187:drug effects*
D000736:Androstenes; D004338:Drug Combinations; D000451:Mineralocorticoid Receptor Antagonists; C035144:drospirenone